News June 4, U.
Since the BIOMab was to be priced at international prices approx. Also, the company aimed to make it affordable to the Indian customers, most of whom did not have a health insurance. This one treatment, albeit expensive, is still affordable by the middle income families in India; especially when it provides such promising results.
What is the decision making unit in this case? The decision making unit: The decision making unit consists the patient and their families firstly, when they decide whether to and what type of treatment to go through, based on the doctors recommendation.
BIOMab could be sold directly to doctors, who suggest the treatment to the patients. Here, the decision makers are mostly the doctors, as patients generally trust the recommended treatment.
Also, it could be sold through traditional pharmacies, which allows them to deliver to the needs of some doctors who recommended these outlets to patients.
Thus the target market and thus, the decision makers consists of the specialists of the less than oncologists in the market as explained by Basak. Since the doctors depend a lot on sales reps to educate the families and patients, it is not unusual for the sales reps to spend two to three hours with the patient explaining the product and its usage.
As mentioned in the case, being a life threatening disease, there is high anxiety among the patients and families. These families seek assurance and trust with the doctor and the pharmacy.
The Biocon’s Launching a New Cancer Drug in India Case Case Study The Biocon’s Launching a New Cancer Drug in India Case and over other 29,+ free term papers, essays and research papers examples are available on the website!. Autor: Nejdet Erdoğan • December 14, • Case Study • Words (3 Pages) • 1, Views. Mumbai: India's Biocon has received approval in the US for a biosimilar it has developed with Mylan to treat cancer patients. Both the companies announced that the US Food and Drug Administration (FDA) has approved the drug to be marketed under brand nameFulphila. It is a biosimilar to Amgen's. Biocon: Launching a New Cancer Drug in India, HSBP Daktronics (A): The Digital Signage Industry In , HSBP NA Early Stage Business Vignettes, HBSP E Langer Lab, HSBP Viagra In China, HSBP HKU Tablet Teach Opportunity Analysis, HSBP KEL Stanford Business School Cases.
The aim of the company is to provide exactly this and thus gain competitive advantage.Biocon: Launching a new cancer drug in India Pros and Cons for Different Strategies Product Delaying the launch of BIOMAb to wait for 3rd phase results.
Get all the latest industry news in your inbox.
The Food and Drug Administration has approved the first biosmilar to treat HER2-positive breast cancer and certain gastric cancers, the agency. Biocon Ltd, Asia's premier biopharmaceuticals company, has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian and brain cancers, in India.
Post navigation ← The Treatment of Outstanding Employee Stock Options in Mergers and Acquisitions Biocon: Launching a New Cancer Drug in India →. The Biocon’s Launching a New Cancer Drug in India Case Case Study The Biocon’s Launching a New Cancer Drug in India Case and over other 29,+ free term papers, essays and research papers examples are available on the website!.
Autor: Nejdet Erdoğan • December 14, • Case Study • Words (3 Pages) • 1, Views. Biocon Chairperson and Managing Director Dr Kiran Mazumdar Shaw, speaking on the occasion, said that with the launch of BIOMAb EGFR, the innovative and cutting edge cancer drugs, the BIO has joined the exclusive league of monoclonal antibody developers worldwide.